Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

FDA warns topical pain relievers can cause burns; FDA issues another DMAA warning letter; Senators blast FDA’s lack of caffeine concern; Perrigo faces guaifenesin delays; Mead Johnson gets back on track in China.

You may also be interested in...



Perrigo CEO Seeks To Check Negative Stock Response

Perrigo CEO Joseph Papa tries to reassure analysts that the acquisition of Elan in July did not signal a shift in strategy, but rather an opportunity to better fund the firm’s core strategy to grow through category and geographic expansion. Key categories include ophthalmology, adult nutrition and products for diabetics.

Perrigo CEO Seeks To Check Negative Stock Response

Perrigo CEO Joseph Papa tries to reassure analysts that the acquisition of Elan in July did not signal a shift in strategy, but rather an opportunity to better fund the firm’s core strategy to grow through category and geographic expansion. Key categories include ophthalmology, adult nutrition and products for diabetics.

Mead Johnson Upbeat On China Outlook After Series Of Setbacks

The infant nutritionals firm has put a poorly timed price increase behind it and is optimistic about the effects of a Hong Kong limit on formula exports on China sales. Additionally, a recall of Danone baby nutrition products in Asia is expected to benefit Mead Johnson over the next 9 to 12 months.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS105972

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel